Covid-19 Impact on Induced Pluripotent Stem Cells Market, Global Research Reports 2020-2021

Published On: May 2020

Format: PDF

Publisher: QY Research

Pages: 90

Report ID: 459825

This report covers market size and forecasts of Induced Pluripotent Stem Cells, including the following market information:
Global Induced Pluripotent Stem Cells Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Induced Pluripotent Stem Cells Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Induced Pluripotent Stem Cells Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Induced Pluripotent Stem Cells Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players
Major competitors identified in this market include Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others

Based on the Application:
Academic Research
Drug Development And Discovery
Toxicity Screening
Regenerative Medicine

1.1 Research Scope<br />    1.2 Market Segmentation<br />    1.3 Research Objectives<br />    1.4 Research Methodology<br />        1.4.1 Research Process<br />        1.4.2 Data Triangulation<br />        1.4.3 Research Approach<br />        1.4.4 Base Year<br />    1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth<br />        1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections<br />        1.5.2 Covid-19 Impact: Commodity Prices Indices<br />        1.5.3 Covid-19 Impact: Global Major Government Policy<br />    1.6 The Covid-19 Impact on Induced Pluripotent Stem Cells Industry<br />    1.7 COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends<br /><br />2 Global Induced Pluripotent Stem Cells Quarterly Market Size Analysis<br />    2.1 Induced Pluripotent Stem Cells Business Impact Assessment - COVID-19<br />        2.1.1 Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026<br />    2.2 Global Induced Pluripotent Stem Cells Quarterly Market Size 2020-2021<br />    2.3 COVID-19-Driven Market Dynamics and Factor Analysis<br />        2.3.1 Drivers<br />        2.3.2 Restraints<br />        2.3.3 Opportunities<br />        2.3.4 Challenges<br /><br />3 Quarterly Competitive Assessment, 2020<br />    3.1 By Players, Global Induced Pluripotent Stem Cells Quarterly Market Size, 2019 VS 2020<br />    3.2 By Players, Induced Pluripotent Stem Cells Headquarters and Area Served<br />    3.3 Date of Key Players Enter into Induced Pluripotent Stem Cells Market<br />    3.4 Key Players Induced Pluripotent Stem Cells Product Offered<br />    3.5 Mergers & Acquisitions, Expansion Plans<br /><br />4 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Type<br />    4.1 Introduction<br />        1.4.1 Hepatocytes<br />        1.4.2 Fibroblasts<br />        1.4.3 Keratinocytes<br />        1.4.4 Amniotic Cells<br />        1.4.5 Others<br />    4.2 By Type, Global Induced Pluripotent Stem Cells Market Size, 2019-2021<br /><br />5 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Application<br />    5.1 Overview<br />        5.5.1 Academic Research<br />        5.5.2 Drug Development And Discovery<br />        5.5.3 Toxicity Screening<br />        5.5.4 Regenerative Medicine<br />    5.2 By Application, Global Induced Pluripotent Stem Cells Market Size, 2019-2021<br />        5.2.1 By Application, Global Induced Pluripotent Stem Cells Market Size by Application, 2019-2021<br /><br />6 Geographic Analysis<br />    6.1 Introduction<br />    6.2 North America<br />        6.2.1 Macroeconomic Indicators of US<br />        6.2.2 US<br />        6.2.3 Canada<br />    6.3 Europe<br />        6.3.1 Macroeconomic Indicators of Europe<br />        6.3.2 Germany<br />        6.3.3 France<br />        6.3.4 UK<br />        6.3.5 Italy<br />    6.4 Asia-Pacific<br />        6.4.1 Macroeconomic Indicators of Asia-Pacific<br />        6.4.2 China<br />        6.4.3 Japan<br />        6.4.4 South Korea<br />        6.4.5 India<br />        6.4.6 ASEAN<br />    6.5 Rest of World<br />        6.5.1 Latin America<br />        6.5.2 Middle East and Africa<br /><br />7 Company Profiles<br />    7.1 Fujifilm Holding Corporation<br />        7.1.1 Fujifilm Holding Corporation Business Overview<br />        7.1.2 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product Introduction<br />        7.1.4 Fujifilm Holding Corporation Response to COVID-19 and Related Developments<br />    7.2 Astellas Pharma<br />        7.2.1 Astellas Pharma Business Overview<br />        7.2.2 Astellas Pharma Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.2.3 Astellas Pharma Induced Pluripotent Stem Cells Product Introduction<br />        7.2.4 Astellas Pharma Response to COVID-19 and Related Developments<br />    7.3 Fate Therapeutics<br />        7.3.1 Fate Therapeutics Business Overview<br />        7.3.2 Fate Therapeutics Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.3.3 Fate Therapeutics Induced Pluripotent Stem Cells Product Introduction<br />        7.3.4 Fate Therapeutics Response to COVID-19 and Related Developments<br />    7.4 Bristol-Myers Squibb Company<br />        7.4.1 Bristol-Myers Squibb Company Business Overview<br />        7.4.2 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product Introduction<br />        7.4.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments<br />    7.5 ViaCyte<br />        7.5.1 ViaCyte Business Overview<br />        7.5.2 ViaCyte Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.5.3 ViaCyte Induced Pluripotent Stem Cells Product Introduction<br />        7.5.4 ViaCyte Response to COVID-19 and Related Developments<br />    7.6 Celgene Corporation<br />        7.6.1 Celgene Corporation Business Overview<br />        7.6.2 Celgene Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.6.3 Celgene Corporation Induced Pluripotent Stem Cells Product Introduction<br />        7.6.4 Celgene Corporation Response to COVID-19 and Related Developments<br />    7.7 Aastrom Biosciences<br />        7.7.1 Aastrom Biosciences Business Overview<br />        7.7.2 Aastrom Biosciences Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.7.3 Aastrom Biosciences Induced Pluripotent Stem Cells Product Introduction<br />        7.7.4 Aastrom Biosciences Response to COVID-19 and Related Developments<br />    7.8 Acelity Holdings<br />        7.8.1 Acelity Holdings Business Overview<br />        7.8.2 Acelity Holdings Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.8.3 Acelity Holdings Induced Pluripotent Stem Cells Product Introduction<br />        7.8.4 Acelity Holdings Response to COVID-19 and Related Developments<br />    7.9 StemCells<br />        7.9.1 StemCells Business Overview<br />        7.9.2 StemCells Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.9.3 StemCells Induced Pluripotent Stem Cells Product Introduction<br />        7.9.4 StemCells Response to COVID-19 and Related Developments<br />    7.10 Japan Tissue Engineering<br />        7.10.1 Japan Tissue Engineering Business Overview<br />        7.10.2 Japan Tissue Engineering Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.10.3 Japan Tissue Engineering Induced Pluripotent Stem Cells Product Introduction<br />        7.10.4 Japan Tissue Engineering Response to COVID-19 and Related Developments<br />    7.11 Organogenesis<br />        7.11.1 Organogenesis Business Overview<br />        7.11.2 Organogenesis Induced Pluripotent Stem Cells Quarterly Revenue, 2020<br />        7.11.3 Organogenesis Induced Pluripotent Stem Cells Product Introduction<br />        7.11.4 Organogenesis Response to COVID-19 and Related Developments<br /><br />8 Key Findings<br /><br />9 Appendix<br />    9.1 About US<br />    9.2 Disclaimer<br />